transdermal glp-1 receptor agonist patch clinical trial Patches: Do They Work? GLP-1 receptor agonists and next-generation
Description
Once it was demonstrated that an intravenous infusion of GLP-1 could decrease blood glucose concentrations in patients with type 2 diabetes, the race was on to exploit the properties of this action
57 The confirmatory secondary endpoints analysis included a composite HF endpoint of death from cardiovascular causes or hospitalisation/urgent visit for HF
Elvert, R
Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4
